This complements previous findings that HAGE promoter hypomethylation may be associated with improved OS in AML patients [27] and the finding of an association between high levels of HAGE protein expression and aggressive clinical–pathological features, poor prognosis and worse progression-free survival in breast cancer [28]. This evidence concerns the gene DDX43 and breast cancer.